Pfizer, Inc. (NYSE:PFE) has announced the updated trial results for AROMASIN. The data showed that women experienced a 19% reduction in risk of breast cancer recurrence after switching to Aromasin® after 2.5 years of tamoxifen compared to women who continued with the tamoxifen throughout the full five year treatment. The results were presented at the CTRC-AACR San Antonio Breast Cancer Symposium on Thursday, December 10.
MicroCap Insider is a web-based financial portal that publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors. Sign Up for our Free Stock Newsletter
Pfizer, Inc. is a global pharmaceutical company focused on research. The company is engaged in the discovery, development, manufacture and marketing of prescription medication for humans and animals. The company acquired Encysive Pharmaceuticals, Inc., and Serenex, Inc. in June 2008.
Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer
